Amneal Pharmaceuticals, Inc. (AMRX): Cost of Revenue
$1.91B
Year ended 2025-12-31
$1.89B
Trailing 12 months to 2026-06-30
+10.1%
3-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.91B | +7.4% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $1.77B | +12.7% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $1.57B | +10.2% | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $1.43B | +7.8% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $1.32B | n/c | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $1.33B | +15.9% | 2023-03-03, From 2020-01-01 |
| 2019-12-31 | $1.15B | +22.2% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $938.77M | +85.0% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $507.48M | +20.6% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $420.77M | n/a | 2019-03-01, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $1.91B | +7.4% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $384.40M | +24.1% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $717.44M | +23.6% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $677.17M | +120.9% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $25.50M | n/a |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $2.76B | -2.5% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $2.12B | +5.9% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $1.01B | +12.2% |
| Alkermes plc. (ALKS) | 2025-12-31 | $196.46M | -19.9% |
Compare AMRX, UTHR, BMRN, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗